ATE366745T1 - Mutant er-alpha und nachweissysteme für transaktivierung - Google Patents

Mutant er-alpha und nachweissysteme für transaktivierung

Info

Publication number
ATE366745T1
ATE366745T1 AT00981647T AT00981647T ATE366745T1 AT E366745 T1 ATE366745 T1 AT E366745T1 AT 00981647 T AT00981647 T AT 00981647T AT 00981647 T AT00981647 T AT 00981647T AT E366745 T1 ATE366745 T1 AT E366745T1
Authority
AT
Austria
Prior art keywords
eralpha
mutant
test
transactivation
diagnosing
Prior art date
Application number
AT00981647T
Other languages
English (en)
Inventor
Koichi Saito
Norihisa Ohe
Hideo Satoh
Original Assignee
Sumitomo Chemical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Chemical Co filed Critical Sumitomo Chemical Co
Application granted granted Critical
Publication of ATE366745T1 publication Critical patent/ATE366745T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Mushroom Cultivation (AREA)
AT00981647T 1999-12-07 2000-12-01 Mutant er-alpha und nachweissysteme für transaktivierung ATE366745T1 (de)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
JP34802299 1999-12-07
JP37066799 1999-12-27
JP2000207011 2000-07-07
JP2000220508 2000-07-21
JP2000234053 2000-08-02
JP2000235463 2000-08-03
JP2000235460 2000-08-03
JP2000235461 2000-08-03

Publications (1)

Publication Number Publication Date
ATE366745T1 true ATE366745T1 (de) 2007-08-15

Family

ID=27573667

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00981647T ATE366745T1 (de) 1999-12-07 2000-12-01 Mutant er-alpha und nachweissysteme für transaktivierung

Country Status (8)

Country Link
US (1) US7582476B2 (de)
EP (1) EP1237925B1 (de)
JP (1) JP4742483B2 (de)
AT (1) ATE366745T1 (de)
AU (1) AU782142B2 (de)
CA (1) CA2393045A1 (de)
DE (1) DE60035522T2 (de)
WO (1) WO2001042307A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002057283A1 (en) * 2001-01-19 2002-07-25 Baylor College Of Medecine Methods and compositions in breast cancer diagnosis and therapeutics
CA2491417A1 (en) * 2002-07-02 2004-01-15 Yamanouchi Pharmaceutical Co., Ltd. Method for screening an agent for improving insulin resistance
US7927840B2 (en) 2006-09-11 2011-04-19 Gen Probe Incorporated Method for detecting West Nile Virus nucleic acids in the 3′ non-coding region
CA2957200C (en) * 2002-10-16 2020-05-26 Gen-Probe Incorporated Compositions and methods for detecting west nile virus
WO2004046352A1 (ja) * 2002-11-15 2004-06-03 Sumitomo Chemical Company, Limited 変異型エストロゲンレセプターαおよびその遺伝子
WO2005040212A2 (en) * 2003-10-24 2005-05-06 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Orthogonal gene switches
FR2863275B1 (fr) * 2003-12-09 2007-08-10 Biomerieux Sa Procede pour le diagnostic/pronostic du cancer du sein
WO2005071080A2 (en) 2004-01-20 2005-08-04 Isis Pharmaceuticals, Inc. Modulation of glucocorticoid receptor expression
JP2006153656A (ja) * 2004-11-29 2006-06-15 Olympus Corp 反応カプセル、反応カプセルを使用した検査方法およびシステム
WO2013063313A1 (en) 2011-10-25 2013-05-02 Isis Pharmaceuticals, Inc. Antisense modulation of gccr expression
WO2014205138A1 (en) 2013-06-19 2014-12-24 Seragon Pharmaceuticals, Inc. Estrogen receptor modulator and uses thereof
MX2015016171A (es) 2013-06-19 2016-08-08 Seragon Pharmaceuticals Inc Moduladores del receptor de estrogeno de azetidina y usos de los mismos.
US9855270B2 (en) 2014-03-13 2018-01-02 Genentech, Inc. Methods and compositions for modulating estrogen receptor mutants
EP3303326B1 (de) 2015-05-26 2020-12-16 H. Hoffnabb-La Roche Ag Heterocyclische östrogen-rezeptormodulatoren und verwendungen davon
US10179676B1 (en) 2017-07-26 2019-01-15 William Hagan Taylor Dispenser with self-closing cap

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7084787A (en) * 1986-02-20 1987-09-09 Karo Bio Ab Eucaryotic expression of steroid receptor proteins
FR2634495B1 (fr) * 1988-07-01 1990-10-26 Chambon Pierre Procede de preparation d'une proteine par des levures utilisant un systeme inductible, vecteurs et souches transformees correspondantes
WO1992008133A1 (en) * 1990-10-29 1992-05-14 Dekalb Plant Genetics Isolation of biological materials using magnetic particles

Also Published As

Publication number Publication date
US20030207380A1 (en) 2003-11-06
JP4742483B2 (ja) 2011-08-10
DE60035522T2 (de) 2008-03-20
US7582476B2 (en) 2009-09-01
EP1237925B1 (de) 2007-07-11
AU782142B2 (en) 2005-07-07
EP1237925A1 (de) 2002-09-11
WO2001042307A1 (en) 2001-06-14
AU1886801A (en) 2001-06-18
CA2393045A1 (en) 2001-06-14
JP2003516137A (ja) 2003-05-13
DE60035522D1 (de) 2007-08-23

Similar Documents

Publication Publication Date Title
DE60035522D1 (de) Mutant er-alpha und nachweissysteme für transaktivierung
Maluf et al. Assessment of DNA damage in lymphocytes of workers exposed to X‐radiation using the micronucleus test and the comet assay
WO2003066876A3 (en) An apparatus and methods for using biological material to discriminate an agent
ATE205884T1 (de) Assays und vorrichtungen zum nachweis von extrahepatischer biliäreratresie
GB2383043A (en) Human genome-derived single exon nucleic acid probes useful for analysis of gene expression in human brain
PL325914A1 (en) Testing apparatus, application thereof, analysing system, method of making such apparatus and method of performing tests by means of such apparatus
DE60233574D1 (de) Verfahren und zusammensetzungen zum nachweis des aktivierungszustands multipler proteine in einzelzellen
ATE515575T1 (de) Verfahren und sonden für den nachweis von krebs
EP2009117A3 (de) Verfahren zur Diagnose von Bauchspeicheldrüsenkrebs
Marshall et al. Importance of minimal residual disease testing during the second year of therapy for children with acute lymphoblastic leukemia
GB2336684A (en) Predicting logarithmic reduction values
BRPI0410283A (pt) métodos de análise de uma região de ácido nucleico marcadora, de detecção ou monitoração de uma população clonal de células em um mamìfero, de diagnóstico e/ou de monitoração de uma condição de doença de mamìfero e de enriquecimento de uma população de moléculas de ácido nucleico em uma amostra biológica
WO2005052592A3 (en) Methods for diagnosis, stratification, and monitoring of alzheimer’s disease
RU2003106971A (ru) Способ оценки качества тестирующей полоски, устройство и считываемый компьютером носитель
DE60023905D1 (de) Optisches system analyse für zellen
DK1520039T3 (da) Mitokondrisk polymorfi, forbundet til en prædisposition til udvikling af uhensigtsmæssig ardannelse og fibrose
BR9902790A (pt) Interface de usuário para um sistema analisador biomédico
ATE317451T1 (de) Verfahren zur diagnose, erkennung, und einstufung von dickdarmkrebs
DE69841164D1 (de) Sphingosin-1-phosphat-lyase polypeptide, polynukleotide und modulierende mitteln, und verfahren zu deren verwendung
DE69721551D1 (de) Proteom-analyse zum charakterisieren von auf- und abgeregelten proteinen in biologischen proben
DE69528703D1 (de) VERFAHREN, REAGENZIEN UND TESTSATZ ZUR DIAGNOSE UND GEZIELTE SIEBTESTUNG FÜR p53 MÜTATIONEN
Duffy et al. Daily and weekly mood ratings using a remote capture method in high‐risk offspring of bipolar parents: Compliance and symptom monitoring
Cole et al. Biomonitoring of possible human exposure to environmental genotoxic chemicals: lessons from a study following the wreck of the oil tanker Braer
Suk et al. Human biomonitoring: research goals and needs
WO2007015113A3 (en) New protein isoforms of the pif-family and uses thereof

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties